Junko Tanizaki

3.7k citations

69 papers · 2.3k indexed · 1 hit paper · h-index 24

Oncology top 1%
- Cancer Immunotherapy and Biomarkers 16
- Lung Cancer Research Studies 15
- HER2/EGFR in Cancer Research 12
Pulmonary and Respiratory Medicine top 2%
- Lung Cancer Treatments and Mutations 41
- Lung Cancer Diagnosis and Treatment 8
Cancer Research top 10%
Hepatology top 5%
Immunology top 10%
Molecular Biology
- PI3K/AKT/mTOR signaling in cancer 7
- Cancer therapeutics and mechanisms 5
Radiology, Nuclear Medicine and Imaging
- Radiomics and Machine Learning in Medical Imaging 5

Co-authors: Kazuhiko Nakagawa Isamu Okamoto Hidetoshi Hayashi Kazuto Nishio Kazuko Sakai Kaoru Tanaka Koji Haratani Masayuki Takeda
Cited by: Oncology Pulmonary and Respiratory Medicine Cancer Research
Journals: Angewandte Chemie International Edition (1 paper)Journal of Clinical Oncology (7 papers)Cancer Research (3 papers)
Partner nations: Japan United States China

In The Last Decade

Junko Tanizaki

66 papers receiving 2.3k citations

Hit Papers

align trajectories log scale

Peers

Countries citing papers authored by Junko Tanizaki

Since Specialization

Citations

This map shows the geographic impact of Junko Tanizaki's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Junko Tanizaki with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Junko Tanizaki more than expected).

Fields of papers citing papers by Junko Tanizaki

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Junko Tanizaki. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Junko Tanizaki. The network helps show where Junko Tanizaki may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Junko Tanizaki, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Junko Tanizaki Line = papers co-authored together Junko Tanizaki links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	124TiP: TROPION-Lung15: A phase III study of datopotamab deruxtecan (Dato-DXd) ± osimertinib vs platinum doublet chemotherapy in patients with EGFR-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC) and disease progression on prior osimertinib Journal of Thoracic Oncology ·E. Nadal,P.K. Cheema,Yi‐Long Wu,M-J. Ahn,Junko Tanizaki,S. Gharagoozloo,Emily Nizialek,Xiaohan Shi,Toon van der Gronde,Helena A. Yu,D.S.W. Tan	2025	1
2	Paraneoplastic Syndromes Mimicking Dermatomyositis and Remitting Seronegative Symmetrical Synovitis With Pitting Edema (RS3PE) Syndrome in Cancer of Unknown Primary Origin: A Case Report Cureus ·S Mochizuki,Ryuichi Ohta,Yuki Konya,Kosuke Isomoto,Takayuki Takahama,Junko Tanizaki,Hidetoshi Hayashi	2025	0
3	Hemophagocytic lymphohistiocytosis induced by nivolumab/ipilimumab combination therapy: A case of lung adenocarcinoma that responded to early steroid pulse therapy Cancer Reports ·Satoru Hagiwara,Junko Tanizaki,Hidetoshi Hayashi,Yoriaki Komeda,Naoshi Nishida,Akihiro Yoshida,Tomoki Yamamoto,Takuya Matsubara,Masatoshi Kudo	2024	1
4	Dual single‑nucleotide polymorphism biomarker combination for opioid selection to treat cancer pain Molecular and Clinical Oncology ·Yoshihiko Fujita,Hiromichi Matsuoka,Yasutaka Chiba,Junji Tsurutani,Takeshi Yoshida,Kiyohiro Sakai,Miki Nakura,Ryo Sakamoto,Chihiro Makimura,Yoichi Ohtake,Kaoru Tanaka,Hidetoshi Hayashi,Takayuki Takahama,Junko Tanizaki,Atsuko Koyama,Kazuto Nishio,Kazuhiko Nakagawa	2024	1
5	A phase 3 global study of telisotuzumab vedotin versus docetaxel in previously treated patients with c-Met 0verexpressing, EGFR wildtype, locally advanced/metastatic nonsquamous NSCLC (TeliMET NSCLC-01). Journal of Clinical Oncology ·Shun Lü,Jonathan W. Goldman,Junko Tanizaki,Hiroaki Akamatsu,Summer Xia,Christine K. Ratajczak,Martha Li,Ellen Bolotin,Jabed Seraj,Antonio Lugini	2024	4
6	Phase Ia/Ib trial on the safety and efficacy of mobocertinib in combination with T-DM1 for patients with HER2-mutant solid tumors (WJOG16022M). Journal of Clinical Oncology ·Hiroaki Kanemura,Junko Tanizaki,Koji Matsumoto,Toshiki Masuishi,Taichi Isobe,Hiroaki Kodama,Toshio Shimizu,Yu Sunakawa,Yasutaka Chiba,Nobuyuki Yamamoto,Kazuhiko Nakagawa,Hidetoshi Hayashi	2024	2
7	LBA8 Phase II trial of atezolizumab plus carboplatin and paclitaxel in patients with metastatic or recurrent thymic carcinoma: Marble study Annals of Oncology ·Tomoyasu Mimori,Takehito Shukuya,Y. Goto,Takayuki Asao,Kōji Takayama,Kyoichi Kaira,Hiroaki Tanaka,Richard Ko,Yukari Tsubata,M. Tachihara,Takuji Suzuki,Junko Tanizaki,S. Sugawara,Y. Zenke,Yoko Shirai,Tsuyoshi Hayashi,Kazuhiko Mori,K. Takahashi	2024	3
8	600TiP Phase III study of telisotuzumab vedotin (Teliso-V) vs docetaxel in pretreated c-Met overexpressing EGFR wildtype (WT) non-squamous (NSQ) locally advanced/metastatic non-small cell lung cancer (a/mNSCLC) Annals of Oncology ·Junko Tanizaki,H. Akamatsu,Jian Su,G-W. Lee,Meng Xia,Barbara E. Ainsworth,M. Li,Ellen Bolotin,J. Seraj,Shun Lü	2023	0
9	KRAS Inhibitor Resistance in MET -Amplified KRAS G12C Non–Small Cell Lung Cancer Induced By RAS- and Non–RAS-Mediated Cell Signaling Mechanisms Clinical Cancer Research ·Shinichiro Suzuki,Kimio Yonesaka,Takeshi Teramura,Toshiyuki Takehara,Ryoji Kato,Hitomi Sakai,Koji Haratani,Junko Tanizaki,Hisato Kawakami,Hidetoshi Hayashi,Kazuko Sakai,Kazuto Nishio,Kazuhiko Nakagawa	2021	66
10	A Randomized Phase II Study Comparing Nivolumab with Carboplatin–Pemetrexed for EGFR -Mutated NSCLC with Resistance to EGFR Tyrosine Kinase Inhibitors (WJOG8515L) Clinical Cancer Research ·Hidetoshi Hayashi,Shunichi Sugawara,Yasushi Fukuda,Daichi Fujimoto,Satoru Miura,Keiichi Ota,Yuichi Ozawa,Satoshi Hara,Junko Tanizaki,Koichi Azuma,Shota Omori,Motoko Tachihara,Kazumi Nishino,Akihiro Bessho,Yasutaka Chiba,Koji Haratani,Kazuko Sakai,Kazuto Nishio,Nobuyuki Yamamoto,Kazuhiko Nakagawa	2021	49
11	MO4-5 A multicenter retrospective study of Oncomine Dx Target Test multi-CDx system for genetic profiling of NSCLC: WJOG13019L Annals of Oncology ·Kentaro Ito,Shinya Sakata,Kohei Otsubo,Atsushi Nakamura,Shunsuke Teraoka,N Matsumoto,Yoshimasa Shiraishi,Koji Haratani,Motohiro Tamiya,Satoshi Ikeda,Satoru Miura,Junko Tanizaki,Shota Omori,Hiroshige Yoshioka,Akito Hata,Hisako Yoshida,Nobuyuki Yamamoto,Kazuhiko Nakagawa	2021	1
12	Impact of EGFR-TKI Treatment on the Tumor Immune Microenvironment in EGFR Mutation–Positive Non–Small Cell Lung Cancer Clinical Cancer Research ·Kohsuke Isomoto,Koji Haratani,Hidetoshi Hayashi,Shigeki Shimizu,Shuta Tomida,Takashi Niwa,Toshihide Yokoyama,Yasushi Fukuda,Yasutaka Chiba,Ryoji Kato,Junko Tanizaki,Kaoru Tanaka,Masayuki Takeda,Takashi Ogura,Tadashi Ishida,Akihiko Ito,Kazuhiko Nakagawa	2020	172
13	Response Heterogeneity of EGFR and HER2 Exon 20 Insertions to Covalent EGFR and HER2 Inhibitors Cancer Research ·Takayuki Kosaka,Junko Tanizaki,Raymond M. Paranal,Hideki Endoh,Christine Lydon,Marzia Capelletti,Claire E. Repellin,Jihyun Choi,Atsuko Ogino,Antonio Calles,Dalia Ercan,Amanda J. Redig,Magda Bahcall,Geoffrey R. Oxnard,Michael J. Eck,Pasi A. Jänne	2017	100
14	Induction of PD-L1 Expression by the EML4–ALK Oncoprotein and Downstream Signaling Pathways in Non–Small Cell Lung Cancerbreakdown → Clinical Cancer Research ·Keiichi Ota,Koichi Azuma,Akihiko Kawahara,Satoshi Hattori,Eiji Iwama,Junko Tanizaki,Taishi Harada,Koichiro Matsumoto,Koichi Takayama,Shinzo Takamori,Masayoshi Kage,Tomoaki Hoshino,Yoichi Nakanishi,Isamu Okamoto	2015	366
15	Identification of Oncogenic and Drug-Sensitizing Mutations in the Extracellular Domain of FGFR2 Cancer Research ·Junko Tanizaki,Dalia Ercan,Marzia Capelletti,Michael Dodge,Chunxiao Xu,Magda Bahcall,Erin M. Tricker,Mohit Butaney,Antonio Calles,Lynette M. Sholl,Peter S. Hammerman,Geoffrey R. Oxnard,Kwok‐Kin Wong,Pasi A. Jänne	2015	30
16	Phase I study of weekly nab‐paclitaxel combined with S‐1 in patients with human epidermal growth factor receptor type 2‐negative metastatic breast cancer Cancer Science ·Junji Tsurutani,Katsumasa Kuroi,Tsutomu Iwasa,Masaki Miyazaki,Shinichi Nishina,Chihiro Makimura,Junko Tanizaki,Kunio Okamoto,Toshinari Yamashita,Tomoyuki Aruga,Takashi Shigekawa,Yoshifumi Komoike,Toshiaki Saeki,Kazuhiko Nakagawa	2015	9
17	Regression of brain metastases from breast cancer with eribulin: a case report BMC Research Notes ·Hiromichi Matsuoka,Junji Tsurutani,Junko Tanizaki,Tsutomu Iwasa,Yoshifumi Komoike,Atsuko Koyama,Kazuhiko Nakagawa	2013	18
18	Activation of HER Family Signaling as a Mechanism of Acquired Resistance to ALK Inhibitors in EML4-ALK–Positive Non–Small Cell Lung Cancer Clinical Cancer Research ·Junko Tanizaki,Isamu Okamoto,Takafumi Okabe,Kazuko Sakai,Kaoru Tanaka,Hidetoshi Hayashi,Hiroyasu Kaneda,Ken Takezawa,Kiyoko Kuwata,Haruka Yamaguchi,Erina Hatashita,Kazuto Nishio,Kazuhiko Nakagawa	2012	126
19	Differential roles of trans-phosphorylated EGFR, HER2, HER3, and RET as heterodimerisation partners of MET in lung cancer with MET amplification British Journal of Cancer ·Junko Tanizaki,Isamu Okamoto,Kazuko Sakai,Kazuhiko Nakagawa	2011	99
20	Enhanced Anticancer Effect of the Combination of BIBW2992 and Thymidylate Synthase–Targeted Agents in Non–Small Cell Lung Cancer with the T790M Mutation of Epidermal Growth Factor Receptor Molecular Cancer Therapeutics ·Ken Takezawa,Isamu Okamoto,Junko Tanizaki,Kiyoko Kuwata,Haruka Yamaguchi,Masahiro Fukuoka,Kazuto Nishio,Kazuhiko Nakagawa	2010	63

About Junko Tanizaki

Junko Tanizaki is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Otorhinolaryngology, having authored 69 papers that have together received 2.3k indexed citations. Recurring topics across this work include Lung Cancer Treatments and Mutations (41 papers), Cancer Immunotherapy and Biomarkers (16 papers), Lung Cancer Research Studies (15 papers), HER2/EGFR in Cancer Research (12 papers), Lung Cancer Diagnosis and Treatment (8 papers), PI3K/AKT/mTOR signaling in cancer (7 papers), Cancer therapeutics and mechanisms (5 papers) and Radiomics and Machine Learning in Medical Imaging (5 papers). The work is most often cited by research in Oncology (1.7k citations), Pulmonary and Respiratory Medicine (1.3k citations) and Cancer Research (287 citations). Junko Tanizaki has collaborated with scholars based in Japan, United States and China. Frequent co-authors include Kazuhiko Nakagawa, Isamu Okamoto, Hidetoshi Hayashi, Kazuto Nishio, Kazuko Sakai, Kaoru Tanaka, Koji Haratani, Masayuki Takeda, Akihiko Ito and Hisato Kawakami. Their work appears in journals such as Angewandte Chemie International Edition, Journal of Clinical Oncology and Cancer Research.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact